# Viela Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viela-bio

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.vielabio.com
- Total disclosed funding: $357M
- Latest round: Series B (Jun 12, 2019)
- Investors on record: 11

## About

Based in Maryland, US, and founded in 2018, Viela Bio, Inc., operates as a biotechnology company that researches, develops, and commercializes novel therapies for autoimmune neuromuscular disorders and severe inflammatory diseases. The company raised its series B funding in June 2019, went public on the NASDAQ market in October 2019, and had its first US Food and Drug Administration (FDA)-approved treatment in June 2020. Their two offices and research labs in Maryland are located in Gaithersburg and Rockville. In February 2021, Horizon Therapeutics acquired all the issued and outstanding shares of Viela Bio's common stock in a two-step cash tender offer.

Viela Bio’s team of researchers develops therapies using various target molecules such as the inebilizumab-cdon (Anti-CD19 mAb) for neuromyelitis optica spectrum disorder (NMOSD), myasthenia gravis (MG), kidney transplant desensitization, and other diseases associated with CD19-expressing B cells (plasma cells) that generate IgG4 antibodies. Their FDA-approved therapy UPLIZNA ® is a B-cell depleter for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive. Other target molecules are the VIB4920 (Anti-CD40L-Tn3 Fusion Protein) which is in development for the treatment of Sjögren's Syndrome, kidney transplant rejection, and rheumatoid arthritis; and VIB7734 (Anti-ILT7 mAb) which is in development for systemic lupus erythematosus, cutaneous lupus erythematosus, and COVID-19-related acute lung injury.

Viela Bio’s revenue is generated through the sales of their commercialized product, UPLIZNA®. Additional clinical trials are being done by the company to further their research and development of their target molecules to be able to commercialize therapies for other autoimmune neuromuscular disorders and inflammatory diseases.

## Funding rounds

- Series B, Jun 12, 2019, $75M — Temasek Holdings, HBM Partners, Viking Global Investors, Goldman Sachs Asset Management, Cormorant Asset Management, Barer & Son Capital, Terra Magnum Capital Partners
- Series A, Feb 23, 2018, $282M — Temasek Holdings, Boyu Capital, Hillhouse Investment, 6 Dimensions Capital, Sirona Capital

## Investors

- Temasek Holdings — Series A, Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series A
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Barer & Son Capital — Series B
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B